You won't find them on financial statements, and they're not easily traded. But invisible assets can hold significant value, ...

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly ...

Fourth quarter results reflect revenue growth, margin expansion and order momentum. Revenue increased 17% to $143.4 million, ...

Revenue up 58% in Fourth Quarter, 53% for Year; Member Growth of 55% for YearAchieves Positive Net Income in Fourth Quarter; Significantly Narrows Net Loss for Full Year Delivers Positive Adjusted EBI ...

Good day, and welcome to the B&G Foods Fourth Quarter and Fiscal 2025 Earnings Call. Today's call, which is being recorded, is scheduled to last about 1 hour, including remarks by B&G Foods management ...

As Washington state lawmakers consider an income tax on earnings over $1 million, a 1933 state Supreme Court decision still reverberates.

Q4 2025 Earnings Call March 5, 2026 12:15 PM ESTCompany ParticipantsLucian Grainge - Chairman & CEOMichael Nash ...

Continued strong financial results and cash generation, achieving all 2025 guidance metrics Full year earnings growth; GAAP EPS up 3% , Adjusted ...

Fourth Quarter Net Income Increased 9% to $7 Million; Adjusted EBITDA Increased 34% to $29 Million Full Year 2025 Revenue ...

Due to the impact of portfolio rationalization, and considering the challenging business environment, the company expects a ...

The INDEXO financial services group concluded 2025 as a year of strong growth across all key areas of operation. IPAS INDEXO, the parent company of the INDEXO financial services group, generated a pro ...

PRAME Cell Therapy: Global, randomized, controlled Phase 3 trial, SUPRAME, in previously treated advanced melanoma ongoing; anzu-cel received Orphan Drug Designation from the FDA for the treatment of ...